SCHEMBL1680711

SCHEMBL1680711

NCc1ccc(OCc2ccccc2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.47
LOX P28300 4/20 0.46
LOXL2 Q9Y4K0 3/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2E1 P05181 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2B6 P20813 1/20 0.46
FFAR1 O14842 2/20 0.43
LTA4H P09960 1/20 0.42
MAOA P21397 2/20 0.42
GAA P10253 2/20 0.42
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
IDO1 P14902 1/20 0.41
AGXT P21549 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1680585 0.81 MAOB (0.50) MAOBCYP3A4MAOAL3MBTL1TDP1
SCHEMBL9053555 0.78 LTA4H (0.40) MAOBCYP2C19FFAR1LTA4HMAOA
SCHEMBL922635 0.74 CYP2E1 (0.48) LOXLOXL2CYP2C19CYP2E1CYP3A4
SCHEMBL23121720 0.73 CD274 (0.63) L3MBTL1RAB9ASMN1; SMN2LMNA
SCHEMBL4159497 0.71 PARP10 (0.51) MAOBCYP2C19CYP2C9FFAR1CYP1A2
SCHEMBL1680417 0.71 CYP2A6 (0.53) LOXLOXL2CYP2C19CYP2E1CYP3A4
SCHEMBL1680710 0.70 MAOB (0.50) MAOBCYP2C19MAOAGAAMAPT
SCHEMBL1680795 0.70 PPARG (0.48) MAOBCYP2C19LTA4HMAOAGAA
SCHEMBL12351987 0.70 LMNA (0.38) MAOBCYP2C19MAOAGAAMAPT
SCHEMBL1680594 0.66 TSHR (0.44) MAOBCYP2C19MAOAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND NAKAMOTO KAZUTAKA 2011-08-11 US disclosed
US-7932272-B2 Antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-04-26 US disclosed
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195999-A1 NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND ERG28, CYP51A1, XPO1 MAOB 1175/4885LOX 1881/4885LOXL2 1131/4885
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD MAOB 2220/4885LOX 3392/4885LOXL2 3565/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 MAOB 1205/4885LOX 2211/4885LOXL2 1401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.